文献类型：期刊文献

英文题名：Design of a Multi-Valent SARS-CoV-2 Peptide Vaccine for Broad Immune Protection via Deep Learning

作者：Feng, Ziyan[1];Pang, Xuelian[1];Xu, Qian[1];Gu, Zijie[1];Li, Shiliang[2];Zhu, Lili[1];Li, Honglin[1,2,3]

机构：[1]East China Univ Sci & Technol, Sch Pharm, Shanghai Key Lab New Drug Design, Shanghai 200237, Peoples R China;[2]East China Normal Univ, Innovat Ctr AI & Drug Discovery, Sch Pharm, Shanghai 200062, Peoples R China;[3]Lingang Lab, Shanghai 200031, Peoples R China

年份：2025

卷号：52

起止页码：142

外文期刊名：ENGINEERING

收录：;EI(收录号：20253619112666);WOS:【SCI-EXPANDED(收录号:WOS:001585569500001)】；

基金：This work was supported in part by the National Natural Science Foundation of China (82150208 and 82425104) , the National Key Research and Development Program of China (2022YFC3400501) , and the Shanghai Rising-Star Program (23QA1402800) .

语种：英文

外文关键词：SARS-CoV-2; Deep learning; ConFormer; Multi-epitope vaccine; T -cell immunity

摘要：The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants capable of evading both convalescent and vaccine-triggered antibody responses has underscored the pivotal role of T-cell immunity in antiviral defense. Here, we develop the ConFormer network for epitope prediction, which couples convolutional neural network (CNN) local features with Transformer global representations to enhance binding prediction performance, and employ the deep learning algorithm and bioinformatics workflows to identify conserved T-cell epitopes within the SARS-CoV-2 proteome. Five epitopes are identified as potential inducers of T-cell immune responses. Notably, the multi-valent vaccine composed of these five peptides significantly activates cluster of differentiation (CD)8' and CD4' T cells both in vitro and in vivo. The serum of mice immunized with this vaccine is able to neutralize the five major SARS-CoV-2 variants of concern. This study provides a candidate peptide vaccine with the potential to trigger antiviral T-cell responses, thereby offering the prospect of immune protection against SARS-CoV-2 variants. (c) 2025 THE AUTHORS. Published by Elsevier LTD on behalf of Chinese Academy of Engineering and Higher Education Press Limited Company. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).